AIMT News and Press, Aimmune Therapeutics Inc. From 08/31/20

Nestle's ( OTCPK:NSRGY ) Health Scinece division (NHSc) has entered into a definitive agreement to acquire peanut allergy treatment maker Aimmune Therapeutics (NASDAQ: AIMT ) . More news on: Nestlé S.A., Aimmune Therapeutics, Inc., Nestlé S.A., Healthcare stocks news, Re...

Sociétés des Produits Nestlé S.A., part of Nestlé Health Science, to acquire Aimmune for $34.50 per share in cash, representing a total equity value of $2.6 Billion and a 174% premium to Aimmune’s closing price on August 28, 2020 Aimmune’s PALFORZIA &#...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that findings from APPEAL-2 ( A llergy to P eanuts Im P acting E motions A nd L ife-2), the largest cross-secti...

Investors had high expectations for Aimmune Therapeutics (NASDAQ: AIMT) at the beginning of the year. Its stock performed well in 2019 -- with its shares surging by more than 30% -- and the biotech was on the verge of getting approval from the U.S. Food and Drug Administration (FDA) for Palf...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healt...

Volatility watch: Short interest is in an uptrend for Vale (NYSE: VALE ) , Nokia (NYSE: NOK ) , United Airlines (NASDAQ: UAL ) , Micron Technology (NASDAQ: MU ) and Denbury Resources (NYSE: DNR ) , while GameStop (NYSE: GME ) , National Beverage (NASDAQ: FIZZ ) and Dillard's (NYSE:...

Image source: The Motley Fool. Aimmune Therapeutics   (NASDAQ: AIMT) Q2 2020 Earnings Call Jul 30, 2020 , 4:30 p.m. ET Operator Continue reading

Aimmune Therapeutics, Inc. (AIMT) Q2 2020 Earnings Conference Call July 30, 2020, 16:30 ET Company Participants DeDe Sheel - VP, IR Jayson Dallas - President, CEO & Director Daniel Adelman - Chief Medical Officer Andrew Oxtoby - Chief Commercial Officer Eric Bjerkholt - C...

Aimmune Therapeutics (NASDAQ: AIMT ) : Q2 Non-GAAP EPS of -$0.81; GAAP EPS of -$1.06 beats by $0.03 . More news on: Aimmune Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

PALFORZIA ® launch gaining momentum as allergist offices begin to re-open EU and Swiss regulatory reviews for PALFORZIA remain on schedule Enrollment in phase 3 POSEIDON trial has resumed    $318 million cash, cash equivalents and investments Cost c...